MedTrace Logo

GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

NCT00617279 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-01-12

Study results available
· View outcomes & findings →

Summary

The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.

Conditions

  • Peripheral Arterial Occlusive Disease

Interventions

DEVICE

GORE PROPATEN Vascular Graft

Arterial Occlusion Bypass

PROCEDURE

Disadvantaged Autologous Vein Graft

Arterial Occlusion Bypass

Sponsors & Collaborators

  • W.L.Gore & Associates

    lead INDUSTRY

Principal Investigators

  • Richard F. Neville, MD · Georgetown University Hospital

  • Jennifer Recknor, Ph.D. · W.L.Gore & Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617279 on ClinicalTrials.gov